Wirksamkeit ausgewählter Substanzen auf das Wachstum von Metazestoden des Echinococcus multilocularis
Efficacies of selected drugs against in vitro cultivated Echinococcus multilocularis metacestodes: Alveolar echinococcus is a highly lethal parasitic disease in humans. It is caused by the larval stage (Metacestode) of tapeworm Echinococcus multilocularis (E. multilocularis). Two chemotherapeutics are licensed for the treatment, Albendazole (Eskazole R) and Mebendazole (Vermox forte R). Undesired side-effects and non-response to the therapy can be reason to terminate the treatment. Alternative drugs and lower dose of Albendazole or Mebendazole are necessary. E. multilocularis vesicles, which were grown intraperitoneally into mice, were transferred into culture flasks together with human liver cell line hep-G2. We evaluated macroscopically and microscopically the effect of following Anthelmintics at various concentrations: Albendazole, praziquantel and ivermectin. Neither ivermectin nor praziquantel damaged E. multilocularis vesicles. Low concentration of Albendazole (0.1 myg/ml) caused 50 % damage after 12 - 13 days. While combination of praziquantel together with Albendazole caused 50 % damage of E. multilocularis vesicles after 2 - 3 days, ivermectin together with low concentration of Albendazole created 50 % damage after 4 - 5 days. We combined in another test series the protease inbibitor Ritonavir, a cytochrom-p450-inhibitor, with Albendazole. Remarkably, 50 % damage of E. multilocularis vesicles was after 3 - 4 days achieved. Maybe a baby-dose Ritonavir modified the metabolism of Albendazole. These combinations could be a possible alternative to standard therapy. Our results encourage the implementation of pre-clinical trials in vivo to secure these effects.
Subject HeadingsFuchsbandwurm [GND]
Echinococcus multilocularis [MeSH]
Parasitic diseases [MeSH]